- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06687434
Carb Counting vs. Simplified Qualitative Meal-Size Estimation
Carb Counting vs. Simplified Qualitative Meal-Size Estimation- A Randomized Control Trial
The goal of this study is to compare qualitative meal-size estimation to accurate carb counting in adolescents with Type One Diabetes using all available AID (Automated Insulin Delivery) systems. We will compare glucose control parameters and patient related outcome measures between the groups. 120 children and adolescents with type 1 Diabetes who begin using AID system will be randomly assigned to one of two groups: simplified qualitative meal size estimation or accurate carb counting. The study will last 6 months, with an additional optional follow up points at 12 and 24 months.
In the first visit all patients will receive nutrition guidance from the dietitian. In the accurate carb counting group, participants will use precise carb counting to manage their meals. In the simplified qualitative meal-size estimation group, participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment. During the study, the dietitian will evaluate the insulin-to-carb ratio and meal estimation at least once in the first two weeks.
Follow-up visits will be scheduled at 4-6 weeks, 3, and 6 months after the study's initiation. At each visit participants will upload their data from their AID systems. Evaluation of their diabetes control will be made and an assessment regarding the carbohydrates calculation method. Digital questionnaires assessing diabetes distress, disordered eating behaviors, dietary regimen, and eating patterns will be provided at the beginning of the study and after 6 months, with an additional optional follow-up points that will be held at 12 and 24 months after the study's initiation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tal Oron, DR.
- Phone Number: 972-544-290-296
- Email: talo@clalit.org.il
Study Contact Backup
- Name: Michal Gilon Keren, Phd
- Phone Number: 972-524-311292
- Email: michalgk@clalit.org.il
Study Locations
-
-
-
Petah tikva, Israel, 4920235
- Recruiting
- Schneider Children's Medical Center
-
Contact:
- Alona Hamou, Msc
- Phone Number: 972-545-950277
- Email: alonah@clalit.org.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- T1D- diagnosed
- Age 6-18 years
- Treated with insulin (multiple daily injections or pump) and intending to initiate treatment with AID systems
Exclusion Criteria:
- Non-T1D
- Unstable medical conditions (other than diabetes) that may impact weight or diabetes management (as severe psychiatric disorders, various syndromes)
- Use of medications that may impact weight or diabetes management (as use of steroids for an extended period of time. use of GLP-1)
- Inability to understand the information, material and questionnaires of the study -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Accurate carb counting
Participants will use precise carb counting to manage their meals
|
Participants will use precise carb counting to manage their meals
|
|
Experimental: Simplified qualitative meal-size estimation
Participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian assessment.
|
participants will use a simplified meal announcement based on three presets for each meal, small, medium, or large, which will be personalized based on the dietitian's assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of time in target range (70-18mg/dl)
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
|
Screening, after 4-6 weeks, after 3 months and after 6 months
|
|
Hemoglobin A1C
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
|
Screening, after 4-6 weeks, after 3 months and after 6 months
|
|
Percentage Continuous glucose monitoting usage
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
|
Screening, after 4-6 weeks, after 3 months and after 6 months
|
|
Number of Episodes of severe hypoglycemia
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
|
Screening, after 4-6 weeks, after 3 months and after 6 months
|
|
Number of episodes of Diabetic Ketoacidosis
Time Frame: Screening, after 4-6 weeks, after 3 months and after 6 months
|
Screening, after 4-6 weeks, after 3 months and after 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total daily insulin dose
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
basal insulin dose
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Number of manual boluses per day
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Number of announced meals per day
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Daily carbohydrates input
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Percentage of automated insulin delivery use
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Number of automated insulin delivery exits per week
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Percentage of automated boluses
Time Frame: at screening, after 4-6 weeks, after 3 months and after 6 months.
|
at screening, after 4-6 weeks, after 3 months and after 6 months.
|
|
Score of Diabetes distress according to questionnaire
Time Frame: At screening and after 6 months
|
At screening and after 6 months
|
|
Score of Disordered eating behaviors according to quesiotnnaire
Time Frame: At screening and after 6 months
|
At screening and after 6 months
|
|
Score of Dietary regimen according to questionnaire
Time Frame: At screening and after 6 months
|
At screening and after 6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC-0411-24ctil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Sultan Qaboos UniversityUniversity of Mosul; University of Child Health Sciences and Children's Hospital...Not yet recruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
Lund UniversityEnrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 DiabetesSweden
-
Superior UniversityActive, not recruitingType 2 Diabetes Mellitus 1Pakistan
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Immunocore LtdNot yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Abdullah KarsNot yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)Turkey (Türkiye)
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
Clinical Trials on accurate carb counting
-
Dasman Diabetes InstituteMcGill UniversityEnrolling by invitation
-
Kinderkrankenhaus auf der BultMedtronicCompletedType 1 Diabetes Mellitus
-
Ege UniversityCompleted
-
Cumhuriyet UniversityHacettepe University Scientific Research Projects Coordination UnitCompletedAdolescent | Type 1 Diabetes MellitusTurkey (Türkiye)
-
Tufts UniversityCompletedDyslipidemiaUnited States
-
University Hospital, MontpellierCompletedTermination of PregnancyFrance
-
Shao PengfeiInstitute of Automation, Chinese Academy of SciencesNot yet recruitingProstate Cancer | Prostate Cancer Aggressiveness | Pathology | Prostate Cancer Stage | Prostate Intraductal CarcinomaChina
-
Ignacio J. Amat SantosInstituto de Salud Carlos III; Gerencia Regional de Salud de Castilla y LeonRecruitingSevere Aortic Valve StenosisSpain
-
Université de SherbrookeNestle Health ScienceCompletedAlzheimer Disease | Glucose MetabolismCanada
-
Stanford UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedActivity Adequacy MindsetsUnited States